-
-
-
-
-
-
-
Travere Therapeutics (TVTX) PT Raised to $62 at Citi
-
-
-
-
-
-
-
Piper Sandler Upgrades Travere Therapeutics (TVTX) to Overweight
-
-
-
-
-
-
-
Citi Adjusts Catalyst Call List
-
-
-
-
-
-
-
Stifel on Travere Therapeutics (TVTX): 'FSGS Increases Risk of CRL, Though Delay/Approval Still Possible'
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Travere Therapeutics (TVTX)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Travere Therapeutics (TVTX)
-
-
-
-
-
-
-
Stifel Reiterates Hold Rating on Travere Therapeutics (TVTX)
-
446,723 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

